{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T11:45:42Z","timestamp":1791805542221,"version":"4.3.4"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"S1","license":[{"start":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T00:00:00Z","timestamp":1763424000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T00:00:00Z","timestamp":1763424000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Angiogenesis"],"DOI":"10.1007\/s10456-025-09997-1","type":"journal-article","created":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T13:15:00Z","timestamp":1763471700000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Executive summary of the 15th HHT international scientific conference"],"prefix":"10.1007","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8811-507X","authenticated-orcid":false,"given":"Freya","family":"Droege","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4085-8784","authenticated-orcid":false,"given":"Alexandre","family":"Guilhem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7572-173X","authenticated-orcid":false,"given":"Nicolas","family":"Ricard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3868-5186","authenticated-orcid":false,"given":"Edda","family":"Spiekerkoetter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1920-6450","authenticated-orcid":false,"given":"Ruben","family":"Hermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0570-6104","authenticated-orcid":false,"given":"Elisa","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1043-7030","authenticated-orcid":false,"given":"Sabine","family":"Bailly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8834-5526","authenticated-orcid":false,"given":"Sophie","family":"Dupuis-Girod","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9394-9271","authenticated-orcid":false,"given":"Marianne","family":"Clancy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9712-316X","authenticated-orcid":false,"given":"Cassi","family":"Friday","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,18]]},"reference":[{"issue":"11","key":"9997_CR1","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1056\/NEJMoa2312749","volume":"391","author":"H Al-Samkari","year":"2024","unstructured":"Al-Samkari H et al (2024) Pomalidomide for Epistaxis in Hereditary Hemorrhagic Telangiectasia. N Engl J Med 391(11):1015\u20131027","journal-title":"N Engl J Med"},{"issue":"1","key":"9997_CR2","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s10456-024-09962-4","volume":"28","author":"R Hermann","year":"2024","unstructured":"Hermann R et al (2024) Effect of oral nintedanib vs placebo on epistaxis in hereditary hemorrhagic telangiectasia: the EPICURE multicenter randomized double-blind trial. Angiogenesis 28(1):9","journal-title":"Angiogenesis"},{"issue":"12","key":"9997_CR3","doi-asserted-by":"publisher","first-page":"3166","DOI":"10.1182\/bloodadvances.2023011961","volume":"8","author":"E Zhang","year":"2024","unstructured":"Zhang E et al (2024) Hereditary hemorrhagic telangiectasia may be the most morbid inherited bleeding disorder in women. Blood Adv 8(12):3166\u20133172","journal-title":"Blood Adv"},{"issue":"2","key":"9997_CR4","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1136\/jmg.2009.069013","volume":"48","author":"ME Faughnan","year":"2011","unstructured":"Faughnan ME et al (2011) International guidelines for the diagnosis and management of hereditary haemorrhagic telangiectasia. J Med Genet 48(2):73\u201387","journal-title":"J Med Genet"},{"issue":"9","key":"9997_CR5","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1001\/jama.2012.250","volume":"307","author":"S Dupuis-Girod","year":"2012","unstructured":"Dupuis-Girod S et al (2012) Bevacizumab in patients with hereditary hemorrhagic telangiectasia and severe hepatic vascular malformations and high cardiac output. JAMA 307(9):948\u2013955","journal-title":"JAMA"},{"issue":"2","key":"9997_CR6","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1164\/ajrccm.158.2.9711041","volume":"158","author":"JR Gossage","year":"1998","unstructured":"Gossage JR, Kanj G (1998) Pulmonary arteriovenous malformations. A state of the art review. Am J Respir Crit Care Med 158(2):643\u2013661","journal-title":"Am J Respir Crit Care Med"},{"issue":"24","key":"9997_CR7","doi-asserted-by":"publisher","first-page":"7812","DOI":"10.3390\/jcm13247812","volume":"13","author":"B Gulich","year":"2024","unstructured":"Gulich B, Buecker A, Schneider G (2024) Reperfusion of pulmonary arteriovenous malformations treated by catheter embolization. J Clin Med 13(24):7812","journal-title":"J Clin Med"},{"issue":"8","key":"9997_CR8","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1016\/j.jvir.2024.04.017","volume":"35","author":"A Fish","year":"2024","unstructured":"Fish A et al (2024) Recurrence of pulmonary arteriovenous malformation after embolization in patients with pulmonary hypertension. J Vasc Interv Radiol 35(8):1148\u20131153","journal-title":"J Vasc Interv Radiol"},{"issue":"7752","key":"9997_CR9","doi-asserted-by":"publisher","first-page":"E6","DOI":"10.1038\/s41586-019-1109-3","volume":"568","author":"Q Venot","year":"2019","unstructured":"Venot Q et al (2019) Author Correction: Targeted therapy in patients with PIK3CA-related overgrowth syndrome. Nature 568(7752):E6","journal-title":"Nature"},{"issue":"12","key":"9997_CR10","doi-asserted-by":"publisher","first-page":"100969","DOI":"10.1016\/j.gim.2023.100969","volume":"25","author":"G Canaud","year":"2023","unstructured":"Canaud G et al (2023) Alpelisib for treatment of patients with PIK3CA-related overgrowth spectrum (PROS). Genet Med 25(12):100969","journal-title":"Genet Med"},{"issue":"1","key":"9997_CR11","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1186\/s13023-025-03887-x","volume":"20","author":"J Hessels","year":"2025","unstructured":"Hessels J et al (2025) Family planning, sexual activity and contraception in hereditary hemorrhagic telangiectasia: a European survey study. Orphanet J Rare Dis 20(1):395","journal-title":"Orphanet J Rare Dis"},{"issue":"3","key":"9997_CR12","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/j.ajhg.2013.07.004","volume":"93","author":"WL Wooderchak-Donahue","year":"2013","unstructured":"Wooderchak-Donahue WL et al (2013) BMP9 mutations cause a vascular-anomaly syndrome with phenotypic overlap with hereditary hemorrhagic telangiectasia. Am J Hum Genet 93(3):530\u2013537","journal-title":"Am J Hum Genet"},{"issue":"3","key":"9997_CR13","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1002\/ajmg.a.62584","volume":"188","author":"S Balachandar","year":"2022","unstructured":"Balachandar S et al (2022) Identification and validation of a novel pathogenic variant in GDF2 (BMP9) responsible for hereditary hemorrhagic telangiectasia and pulmonary arteriovenous malformations. Am J Med Genet A 188(3):959\u2013964","journal-title":"Am J Med Genet A"},{"issue":"5","key":"9997_CR14","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1016\/j.ajhg.2019.09.010","volume":"105","author":"DA Snellings","year":"2019","unstructured":"Snellings DA et al (2019) Somatic mutations in vascular malformations of hereditary hemorrhagic telangiectasia result in bi-allelic loss of ENG or ACVRL1. Am J Hum Genet 105(5):894\u2013906","journal-title":"Am J Hum Genet"},{"issue":"10","key":"9997_CR15","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.1016\/j.ajhg.2024.08.020","volume":"111","author":"E DeBose-Scarlett","year":"2024","unstructured":"DeBose-Scarlett E et al (2024) Somatic mutations in arteriovenous malformations in hereditary hemorrhagic telangiectasia support a bi-allelic two-hit mutation mechanism of pathogenesis. Am J Hum Genet 111(10):2283\u20132298","journal-title":"Am J Hum Genet"},{"issue":"14","key":"9997_CR16","doi-asserted-by":"publisher","first-page":"7682","DOI":"10.3390\/ijms25147682","volume":"25","author":"KJ Whitehead","year":"2024","unstructured":"Whitehead KJ et al (2024) Investigation of the genetic determinants of telangiectasia and solid organ arteriovenous malformation formation in hereditary hemorrhagic telangiectasia (HHT). Int J Mol Sci 25(14):7682","journal-title":"Int J Mol Sci"},{"issue":"3","key":"9997_CR17","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1097\/MOH.0000000000000496","volume":"26","author":"SD Castillo","year":"2019","unstructured":"Castillo SD, Baselga E, Graupera M (2019) PIK3CA mutations in vascular malformations. Curr Opin Hematol 26(3):170\u2013178","journal-title":"Curr Opin Hematol"},{"issue":"9","key":"9997_CR18","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.3390\/cells8091079","volume":"8","author":"A Desroches-Castan","year":"2019","unstructured":"Desroches-Castan A et al (2019) Differential consequences of Bmp9 deletion on sinusoidal endothelial cell differentiation and liver fibrosis in 129\/Ola and C57BL\/6 mice. Cells 8(9):1079","journal-title":"Cells"},{"issue":"22","key":"9997_CR19","doi-asserted-by":"publisher","first-page":"2314","DOI":"10.1182\/blood.2023021777","volume":"143","author":"ME Bernabeu-Herrero","year":"2024","unstructured":"Bernabeu-Herrero ME et al (2024) Mutations causing premature termination codons discriminate and generate cellular and clinical variability in HHT. Blood 143(22):2314\u20132331","journal-title":"Blood"},{"issue":"4","key":"9997_CR20","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1093\/hmg\/ddu531","volume":"24","author":"C Mallet","year":"2015","unstructured":"Mallet C et al (2015) Functional analysis of endoglin mutations from hereditary hemorrhagic telangiectasia type 1 patients reveals different mechanisms for endoglin loss of function. Hum Mol Genet 24(4):1142\u20131154","journal-title":"Hum Mol Genet"},{"issue":"9","key":"9997_CR21","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1182\/blood-2010-03-276881","volume":"116","author":"N Ricard","year":"2010","unstructured":"Ricard N et al (2010) Functional analysis of the BMP9 response of ALK1 mutants from HHT2 patients: a diagnostic tool for novel ACVRL1 mutations. Blood 116(9):1604\u20131612","journal-title":"Blood"},{"issue":"2","key":"9997_CR22","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s10456-023-09902-8","volume":"27","author":"T Al Tabosh","year":"2024","unstructured":"Al Tabosh T et al (2024) Impact of heterozygous ALK1 mutations on the transcriptomic response to BMP9 and BMP10 in endothelial cells from hereditary hemorrhagic telangiectasia and pulmonary arterial hypertension donors. Angiogenesis 27(2):211\u2013227","journal-title":"Angiogenesis"},{"issue":"28","key":"9997_CR23","doi-asserted-by":"publisher","first-page":"10963","DOI":"10.1074\/jbc.RA118.002968","volume":"293","author":"E Tillet","year":"2018","unstructured":"Tillet E et al (2018) A heterodimer formed by bone morphogenetic protein 9 (BMP9) and BMP10 provides most BMP biological activity in plasma. J Biol Chem 293(28):10963\u201310974","journal-title":"J Biol Chem"},{"key":"9997_CR24","doi-asserted-by":"publisher","first-page":"13650","DOI":"10.1038\/ncomms13650","volume":"7","author":"R Ola","year":"2016","unstructured":"Ola R et al (2016) PI3 kinase inhibition improves vascular malformations in mouse models of hereditary haemorrhagic telangiectasia. Nat Commun 7:13650","journal-title":"Nat Commun"},{"issue":"11","key":"9997_CR25","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1038\/s44161-024-00550-9","volume":"3","author":"S Dinakaran","year":"2024","unstructured":"Dinakaran S et al (2024) CDK6-mediated endothelial cell cycle acceleration drives arteriovenous malformations in hereditary hemorrhagic telangiectasia. Nat Cardiovasc Res 3(11):1301\u20131317","journal-title":"Nat Cardiovasc Res"},{"issue":"12","key":"9997_CR26","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1161\/CIRCULATIONAHA.122.062952","volume":"149","author":"G Genet","year":"2024","unstructured":"Genet G et al (2024) Induced endothelial cell cycle arrest prevents arteriovenous malformations in hereditary hemorrhagic telangiectasia. Circulation 149(12):944\u2013962","journal-title":"Circulation"},{"issue":"1","key":"9997_CR27","doi-asserted-by":"publisher","first-page":"5891","DOI":"10.1038\/s41467-022-33324-7","volume":"13","author":"NW Chavkin","year":"2022","unstructured":"Chavkin NW et al (2022) Endothelial cell cycle state determines propensity for arterial-venous fate. Nat Commun 13(1):5891","journal-title":"Nat Commun"},{"issue":"8","key":"9997_CR28","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1161\/ATVBAHA.123.319385","volume":"43","author":"X Zhou","year":"2023","unstructured":"Zhou X et al (2023) ANG2 blockade diminishes proangiogenic cerebrovascular defects associated with models of hereditary hemorrhagic telangiectasia. Arterioscler Thromb Vasc Biol 43(8):1384\u20131403","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"1","key":"9997_CR29","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s10456-024-09955-3","volume":"28","author":"Z Diwan","year":"2024","unstructured":"Diwan Z et al (2024) Alk1\/Endoglin signaling restricts vein cell size increases in response to hemodynamic cues. Angiogenesis 28(1):5","journal-title":"Angiogenesis"},{"issue":"1","key":"9997_CR30","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.1038\/s41467-017-01742-7","volume":"8","author":"JS Fang","year":"2017","unstructured":"Fang JS et al (2017) Shear-induced Notch-Cx37-p27 axis arrests endothelial cell cycle to enable arterial specification. Nat Commun 8(1):2149","journal-title":"Nat Commun"},{"issue":"8","key":"9997_CR31","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.3324\/haematol.2020.261859","volume":"106","author":"H Al-Samkari","year":"2021","unstructured":"Al-Samkari H et al (2021) An international, multicenter study of intravenous bevacizumab for bleeding in hereditary hemorrhagic telangiectasia: the InHIBIT-Bleed study. Haematologica 106(8):2161\u20132169","journal-title":"Haematologica"},{"issue":"25","key":"9997_CR32","doi-asserted-by":"publisher","first-page":"2747","DOI":"10.1161\/CIRCULATIONAHA.109.927681","volume":"121","author":"K Abe","year":"2010","unstructured":"Abe K et al (2010) Formation of plexiform lesions in experimental severe pulmonary arterial hypertension. Circulation 121(25):2747\u20132754","journal-title":"Circulation"},{"issue":"2","key":"9997_CR33","doi-asserted-by":"publisher","first-page":"204589401875991","DOI":"10.1177\/2045894018759918","volume":"8","author":"W Li","year":"2018","unstructured":"Li W et al (2018) The clinical characteristics and long-term prognosis of pulmonary arterial hypertension associated with hereditary hemorrhagic telangiectasia. Pulm Circ 8(2):2045894018759918","journal-title":"Pulm Circ"},{"key":"9997_CR34","doi-asserted-by":"publisher","first-page":"102033","DOI":"10.1016\/j.pupt.2021.102033","volume":"68","author":"E Abston","year":"2021","unstructured":"Abston E et al (2021) Treatment of pulmonary hypertension in patients with Hereditary Hemorrhagic Telangiectasia\u2014A case series and systematic review. Pulm Pharmacol Ther 68:102033","journal-title":"Pulm Pharmacol Ther"},{"issue":"16","key":"9997_CR35","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1056\/NEJMoa2213558","volume":"388","author":"MM Hoeper","year":"2023","unstructured":"Hoeper MM et al (2023) Phase 3 trial of sotatercept for treatment of pulmonary arterial hypertension. N Engl J Med 388(16):1478\u20131490","journal-title":"N Engl J Med"},{"issue":"5","key":"9997_CR36","doi-asserted-by":"publisher","first-page":"2401424","DOI":"10.1183\/13993003.01424-2024","volume":"65","author":"MM Hoeper","year":"2025","unstructured":"Hoeper MM et al (2025) Efficacy and safety of the activin signalling inhibitor, sotatercept, in a pooled analysis of PULSAR and STELLAR studies. Eur Respir J 65(5):2401424","journal-title":"Eur Respir J"},{"issue":"3","key":"9997_CR37","doi-asserted-by":"publisher","first-page":"2301107","DOI":"10.1183\/13993003.01107-2023","volume":"62","author":"R Souza","year":"2023","unstructured":"Souza R et al (2023) Effects of sotatercept on haemodynamics and right heart function: analysis of the STELLAR trial. Eur Respir J 62(3):2301107","journal-title":"Eur Respir J"},{"issue":"1","key":"9997_CR38","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1002\/ajmg.a.62522","volume":"188","author":"A Farhan","year":"2022","unstructured":"Farhan A et al (2022) Clinical manifestations of patients with GDF2 mutations associated with hereditary hemorrhagic telangiectasia type 5. Am J Med Genet A 188(1):199\u2013209","journal-title":"Am J Med Genet A"},{"issue":"1","key":"9997_CR39","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1183\/09031936.00126207","volume":"32","author":"CL Shovlin","year":"2008","unstructured":"Shovlin CL et al (2008) Embolisation of pulmonary arteriovenous malformations: no consistent effect on pulmonary artery pressure. Eur Respir J 32(1):162\u2013169","journal-title":"Eur Respir J"}],"container-title":["Angiogenesis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10456-025-09997-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10456-025-09997-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10456-025-09997-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T11:59:56Z","timestamp":1765367996000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10456-025-09997-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,18]]},"references-count":39,"journal-issue":{"issue":"S1","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["9997"],"URL":"https:\/\/doi.org\/10.1007\/s10456-025-09997-1","relation":{},"ISSN":["1573-7209"],"issn-type":[{"value":"1573-7209","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,18]]},"assertion":[{"value":"18 November 2025","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"61"}}